/logo-16545883420.png){kind=logo}
Shenogen’s Feng Chen selected as Beijing Science & Technology New Star
April 23rd, 2014, Beijing, China
Recently, the result of 2014 Beijing Science & Technology New Star Project came out. Dr. Feng Chen, Senior Director of Biology at Shenogen Pharma Group, is on the name list.
Dr. Feng Chen got her PhD degree in biochemistry and molecular biology, Peking Union Medical College (PUMC). She owns 8 year experience in antibody drug and diagnostic reagent R&D, especially in areas of cancer biomarker and targeted antibody therapy. She has authored/ co-authored many articles and comments on both local and foreign journals, as well as co-owned 3 global patents. Prior to joining Shenogen, Dr. Chen was associate researcher in Beijing Cancer Hospital of Peking University, leading several stomach cancer projects. Dr. Chen started working in Shenogen from Aug, 2010, as Senior Director of Biology. Currently she is leading a team dedicated the R&D of antibody and diagnostic kit programs.
The Beijing Science & Technology New Star Project is hosted by Beijing Science and Technology Commission, aimed to raise up promising youth in R&D field. The project started in 1993. The selective youth under 35 year old will get financial support to do research, make international communication and grow up to innovative strategic talents in science and technology fields. 110 New Stars have been selected in 2014. Among them most are from research institutes and colleges, only 27 are from companies and 3 are from biopharma companies.
About Shenogen
Shenogen Pharma Group is a drug discovery and development company based in Beijing, China, that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently in Ph II clinical trial for treatment of advanced hepatocellular carcinoma.